Summary. The in vivo effects of vasoactive intestinal potypeptide (VIP), secretin and two different molecular forms of gastrin, gastrin 17 and pentagastrin, on basal and stimulated insulin secretion have been investigated in the mouse. All these peptides induced a moderate dose-dependent increase in basal insulin secretion. The different polypeptides showed complex effects on insulin release stimulated by glucose, the chotinergic agonist carbachol or the ,6-adrenergic agonist L-isop~opylnor.adrenaline (L-IPNA), these effects being dependent on the nature of the secretagogue. VIP and secretin both potenti 7 ated glucose-induced insulin release. Seeretin inhibited insulin secretion induced by caibachol and L-IPNA, whereas VIP potentiated L-IPNA-induced insulin secretion and had no influence on the effect of carbachol. Gastrin 17 and pentagastrin did not affect glucose-or carbachol-induced insulin release, whereas they inhibited L-IPNA-induced insulin secretion. The results suggest that VIP, secretin and gastrin display their effects on insulin secretion through different mechanisms. The results indirectly suggest the existence of separate insulin secretory pathways which operate differently, or at least partly differently, after glucose stimulation, cholinergie stimulation, and fl-adrenergic stimulation.
IV glucose administration, despite a lower blood glucose level. This potentiated response seems to be due to the release of gastro-intestinal peptides, the socalled incretin effect [3] . Peptides produced by intrapancreatic cells, endocrine and neural, may also regulate insulin secretion by a paracrine effect [4] . Some of these polypeptides show similarities in chemical structure and can therefore be grouped into two families [5] , the glucagon family including glucagon, vasoactive intestinal polypeptide (VIP), secretin, and gastric inhibitory polypeptide (GIP), and the gastrin family including cfiolecystokinin (CCK) and gastrin.
Recently it was demonstrated that some of the newly discovered gastrointestinal polypeptides interfere with the insulin secretory mechanisms in a complex manner, the effects on stimulated insulin secretion being highly dependent on the nature of the secretagogue [6] . The aim of the present investigation was to characterise further the effect of gastrointestinal polypeptides on basal and stimulated insulin release, and to compare effects of peptides belonging to the same polypeptide family with each other and with members of the other family. For this purpose we selected VIP and secretin on one hand and two different molecular forms of gastrin on the other. The in vivo insulin-releasing properties of these polypeptides were investigated under identical experimental conditions in the mouse.
Materials and Methods

Animals
Female mice of the NMRI strain (Laboratory Animal Breeding, Laven, Denmark), weighing 25-35 g, were used. The animals were kept on a standard pellet diet (Astra-Ewos, S/Sdert~ilje, Sweden) with tap water ad libitum before and throughout the experiments.
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Drugs
Pure porcine VIP and pure porcine secretin were kindly donated by Professor V. Mutt, .Karolinska Institutet, Stockholm, Sweden. Pentagastrin (Peptavlon) was obtained from ICI Ltd., Macclesfield, England. Synthetic human gastrin 17 was from Bachem Inc., Torrance, Calif., USA. All peptides were dissolved in 0.154 mol/1 saline with the addition of I g/l gelatine to avoid adsorption. D-glucose and carbachol (British Drug Houses Ltd., Poole, England) and L-isopropylnoradrenaline (L,IPNA) (H~sle AB, Mrlndal, Sweden) were dissolved in 0.154 mol/l saline.
Protocols
L Effects on Basal Insulin Secretion. The peptides were administered IV through a tail vein, in a volume of 10 p.I/g body weight.
Control animals were injected with 0.154 tool/1 saline. After 2 or 5.5 rain 250 ~tl blood was drawn by orbital puncture [7] . The mice were conscious throughout the experiments.
IL Effects on Stimulated Insulin
Secretion. The peptides were injected IV, 5 p.l/g, 15 s prior to a rapid IV injection of 5 gl/g of either D-glucose, carbachol or L-IPNA. Control animals were injected with 0.154 tool/1 saline and one of the secretagogues, or with saline alone. This sequence of the injections was chosen in order to mimic the anticipated humoral insulin releasing influence, when gut peptides released following a meal may reach the islet cells before the nutrients [6] . Two minutes (glucose and carbachol) or 5.5 rain (L-IPNA) after the last injection blood was collected as above. Previous experiments have shown that the maximal concentration of immunoreactive insulin in mouse plasma following a rapid IV injection of these secretagogues was achieved after 2 (glucose and carbachol) and 5.5 (L-IPNA) min, respectively, The secretagogues were administered in doses giving half-maximal insulin secretory responses. These doses were 2.8 mmol/kg (glucose), 160 nmol/kg (carbachol) and 340 nmol/kg (L-IPNA).
Determination of Insulin and Glucose
Plasma immunoreactive insulin concentrations (IRI)were measured by radioimmunoassay [8] using I'-5I-Iabelled porcine insulin and guinea pig anti-porcine-insulin, with porcine insulin as standard. Plasma glucose concentrations were measured with a glucose oxidase method [9] .
Statistics
The results are presented as mean + SEM. Student's t-test was used to test significance.
Results
I. Effects of the Polypeptides on Basal Insulin Secretion
VIP, secretin, gastrin 17 and pentagastrin all induced stimulation of insulin secretion in a dose,dependent manner 2 min after injection (Fig. 1) . At the highest
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B. Ahrdn and L Lundquist: Effects of VIP, Secretin and Gastrin on Mouse Insulin Secretion dose levels studied they increased the plasma IRI concentrations by 8-30 mU/]. Plasma IRI did not differ from control values 5.5min after hormone injection. (Fig. 2) . Injection of VIP, 4.25 nmol/kg (the threshold dose for stimulation of basal insulin secretion), IV 15 s prior to IV injection of one of the secretagogues induced a potentiation of both glucose-and L-IPNA-stimulated insulin secretion, while carbachol-induced insulin release was unaffected. Glucose-stimulated insulin secretion was inreased by 30% (p <0,05), and L-IPNA-induced insulin release by 65% (p <0.01), by VIP. (Fig. 3) . iV injection of secretin, 4.25 nmol/kg, 15 s prior to IV injection of glucose resulted in a potentiation of glucose-induced insulin release. Secretin was more potent than VIP, potentiating the insulin releasing effect of glucose by 90% (p <0.001), In contrast to VIP, secretin inhibited the effects of both carbachol and L-IPNA. Carbacholinduced insulin secretion was inhibited by 35% (p <0.01) and L-IPNA-stimulated insulin release by 30% (p <0,05). (Fig. 4) and~Pentagastrin (Fig. 5) . These peptides exerted identical effects on stimulated insulin release. With IV injection in a dose of 4.25 nmol/ kg 15 s prior to injection of each of the secretagogues neither of them changed the insulin secretory response to glucose or carbachol. However, both peptides inhibited the L-IPNA-induced insulin secretion, gastrin 17 by 35% (p <0.05) and pentagastrin by 20% (p <0.05). 
I[. Effects of the Polypeptides on Stimulated Insulin Secretion a) VIP
b) Secretin
c) Gastrin 17
Plasma Glucose Concentrations ~ ,oo
Plasma glucose concentrations were 8.5 _+ 0.4 mmol/ = 1 in mice not receiving glucose. There was no differ-~, ence in plasma glucose levels between the groups. ~ ~~ Thus none of the polypeptides, nor carbachol and L-IPNA influenced the plasma glucose during the timeperiod studied. Two minutes after glucose injection 0 the plasma glucose concentrations were 15.8 + 1ol retool/1. There was no difference between the glucose-treated groups.
Discussion
The 28 amino acid peptide VIP is presumed to occur in neurones in the gut and pancreas and it has been suggested to be a neurotransmitter [10] [11] [12] [13] amino acid peptide secretin has been shown to occur in endocrine cells in the small intestine [14] . Chemically VIP and secretin resemble glucagon and GIP, and these polypeptides have been grouped in one family [5] . VIP has been shown to have a stimutatory action on insulin release in the'dogand pig [15] [16] [17] [18] and in the perfused cat pancreas [19] , but is reported to have no insulin releasing activity in vivo in the rat [20] . Secretin seems to stimulate insulin secretion in high doses in man [1, 2, [21] [22] [23] and while augmenting glucose-induced insulin release it had no influence on the effect of other secretagogues [22] . In doses that reproduce the level of circulating secretin, however, there was no effect on glucose-induced insulin release [24] .
In the present study we have demonstrated a slight dose-dependent increase of basal plasma insulin levels after administration of VIP or secretin, and these two peptides also potentiated glucose-induced insulin secretion. It is notable that the insulin-releasing activity of the two polypeptides was very weak compared to the effect of glucose and it seems unlikely that they function as important modulators of basal insulin release. In equimolar doses we found secretin to be more potent than VIP in stimulating basal insulin secretion, and also in its ability to potentiate glucose-induced insulin secretion.
VIP and secretin differed in their effects on carbachol-and L-IPNA-induced insulin release. While VIP enhanced the response to fl-adrenergic stimulation it had no effect on cholinergicatly induced insulin secretion. Secretin, on the contrary, inhibited the effects of these two secretagogues. It is thus reasonable to assume that in the,mouse VIP and secretin iiateract with different receptors on the insulin cell. From studies in liver and fat cells it was suggested that the two peptides stimulate the same receptors [25] , whereas on pancreatic acinar cell membranes from the guinea-pig two kinds of VIP/secretin-sensitive receptors have been described [26] . These receptors had different affinities but the same expression for VIP and secretin, respectively. Since the present study demonstrates that some of the effects of VIP and secretin differed it can be suggested that the peptides stimulated less related receptors on the insulin cells.
Gastrin is chemically heterogenous and occurs in several different molecular forms [27] . It has been localized to endocrine cells in the antrum and proximal duodenum [28, 29] . Furthermore it has been demonstrated to occur in endocrine cells in the pancreatic islets during the neonatal period [30] . Recently, gastrin-immunoreactivity was also described in nerves in several organs including the pancreas [13, 31] .
A stimulatory effect on basal as well as on glucose-induced insulin release after administration of gastrin to man and dog has previously been reported [1, 2, 21, [32] [33] [34] . Generally, higher plasma levels of gastrin than are seen under physiological conditions are necessary to obtain an insulin-releasing effect [1] .
We found that both gastrin 17 and pentagastrin stimulate basal insulin release in a dose-dependent manner, but their potency was low. The results suggest that circulating gastrin is of no or little importance for basal insulin release in the mouse.
Gastrin 17 and pentagastrin were found to exert identical effects on stimulated insulin release, suggesting that they interact with the same receptors. Both peptides inhibited L-IPNA-induced insulin release, while showing no influence on glucose-or carbachol-stimulated secretion of insulin. This pattern of effects differed from that of VIP and secretin. It has been suggested that secretin and gastrin act on the same receptors [35] but since the effects on insulin release of gastrin clearly differed from that of secretin, the results of the present study do not favour this hypothesis.
The physiological relevance of these polypeptides for insulin secretion cannot be deduced from this study. Our results show, however, that insulin secretion is influenced by the gastrointestinal polypeptides in a complex way. Interaction of all polypeptides with one type of receptors on the insulin cell cannot explain the results. Furthermore, the effects of the polypeptides on stimulated insulin secretion are highly dependent on the .nature of the secretagogue. The results indirectly suggest that glucose, cholinergic agonists, and/5-adi'energic agonists, respectively, stimulate insulin release by activation of separate or partly separate pathways. The polypeptides could be affecting the receptors of the secretagogues, or initiating intracellular events interacting with those of the secretagogues.
